PT  - JOURNAL ARTICLE
AU  - Sonnleitner, Sissy Therese
AU  - Prelog, Martina
AU  - Sonnleitner, Stefanie
AU  - Hinterbichler, Eva
AU  - Halbfurter, Hannah
AU  - Kopecky, Dominik B. C.
AU  - Almanzar, Giovanni
AU  - Koblmüller, Stephan
AU  - Sturmbauer, Christian
AU  - Feist, Leonard
AU  - Horres, Ralf
AU  - Posch, Wilfried
AU  - Walder, Gernot
TI  - The mutational steps of SARS-CoV-2 to become like Omicron within seven months: the story of immune escape in an immunocompromised patient
AID  - 10.1101/2022.03.04.22271540
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.04.22271540
4099  - http://medrxiv.org/content/early/2022/03/07/2022.03.04.22271540.short
4100  - http://medrxiv.org/content/early/2022/03/07/2022.03.04.22271540.full
AB  - We studied a unique case of prolonged viral shedding in an immunocompromised patient that generated a series of SARS-CoV-2 immune escape mutations over a period of seven months. During the persisting SARS-CoV-2 infection seventeen non-synonymous mutations were observed, thirteen (13/17; 76.5%) of which occurred in the genomic region coding for spike. Fifteen (15/17; 88.2%) of these mutations have already been described in the context of variants of concern and include the prominent immune escape mutations S:E484K, S:D950N, S:P681H, S:N501Y, S:del(9), N:S235F and S:H655Y. Fifty percent of all mutations acquired by the investigated strain (11/22) are found in similar form in the Omicron variant of concern. The study shows the chronology of the evolution of intra-host mutations, which can be seen as the straight mutational response of the virus to specific antibodies and should therefore be given special attention in the rating of immune escape mutations of SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe gratefully acknowledge the financial support of the Austrian Research Promotion Agency (FFG), Grant No. 889135.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval to use residual routinely taken serum samples for retrospective analyses was obtained by the Ethics Committee of the University Hospital Wuerzburg (no. 20201105_01).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe generated full-genome sequences are available at GISAID EpiCoV (https://gisaid.org/no.EPI_ISL_2106191-21061201). https://gisaid.org/no.EPI_ISL_2106191-21061201